No Detail Found!

Efficacy of Neoadjuvant Chemotherapy in Lobular and Rare Subtypes of Breast Cancer

Author(s)
Erdogan Selcuk Seber Department of Medical Oncology, Faculty of Medicine, Tekirdag Namik Kemal University,Tekirdag,Turkiye
Yakup Iriagac Department of Medical Oncology, Faculty of Medicine, Tekirdag Namik Kemal University,Tekirdag,Turkiye; Department of Medical Oncology, Balikesir Ataturk City Hospital, Balikesir, Turkiye
Eyyup Cavdar Department of Medical Oncology, Faculty of Medicine, Tekirdag Namik Kemal University,Tekirdag,Turkiye
Kubilay Karaboyun Department of Medical Oncology, Faculty of Medicine, Tekirdag Namik Kemal University,Tekirdag,Turkiye
Okan Avci Department of Medical Oncology, Faculty of Medicine, Tekirdag Namik Kemal University,Tekirdag,Turkiye
Ahmet Yolcu Department of Medical Oncology, Aydin Adnan Menderes University,Aydin,Turkiye
Sibel Ozkan Gurdal Department of Medical Oncology, Aydin Adnan Menderes University,Aydin,Turkiye
Meltem Oznur Department of Medical Oncology, Aydin Adnan Menderes University,Aydin,Turkiye
Ferhat Ekinci Department of Medical Oncology, Aydin Adnan Menderes University,Aydin,Turkiye
Ali Aytac Department of Medical Oncology, Aydin Adnan Menderes University,Aydin,Turkiye
Ilkay Gulturk Department of Medical Oncology, Bakirkoy Sadi Konuk Training and Research Hospital,Istanbul,Turkiye
Mesut Yilmaz Department of Medical Oncology, Bakirkoy Sadi Konuk Training and Research Hospital,Istanbul,Turkiye
Nadiye Sever Department of Medical Oncology, Marmara University,Istanbul,Turkiye
Tanju Kapagan Department of Medical Oncology, Basaksehir Cam and Sakura City Hospital,Istanbul,Turkiye
Ferhat Ferhatoglu Department of Medical Oncology, Basaksehir Cam and Sakura City Hospital,Istanbul,Turkiye
Fatma Akdag Kahvecioglu Department of Medical Oncology, Faculty of Medicine, Sakarya University,Sakarya,Turkiye
Ilhan Hacibekiroglu Department of Medical Oncology, Faculty of Medicine, Sakarya University,Sakarya,Turkiye
Abstract
Objective: To determine the predictive factors for the pathological complete response (pCR) in patients with non-ductal invasive breast cancer (ND-BC) receiving neoadjuvant chemotherapy. Study Design: Observational study. Place and Duration of the Study: Departments of Medical Oncology, Tekirdag Namik Kemal University, Sirnak State Hospital, Aydin Adnan Menderes University, Marmara University, Bakirkoy Sadi Konuk Hospital, Basaksehir Cam and Sakura Hospital, Sakarya University, Bal1kesir Ataturk Hospital, Turkiye, from April 2016 to December 2022. Methodology: A total of 222 non-metastatic breast cancer patients who received neoadjuvant chemotherapy were included in this retrospective multicentric study. The clinicopathologic data were obtained from the hospitals electronic-record-system. The logistic regression models were used to identify predictive factors for pCR. Results: One hundred and twenty-six patients (56.8%) had invasive lobular carcinoma and 28 patients (12.6%) had signet ring cell/mucinous carcinoma. A total of 45 patients (20.3%) achieved pCR. The pCR rate was 14.3% for lobular carcinoma and 17.9% for signet ring cell/mucinous carcinoma. The univariate analysis showed that estrogen receptor-negative tumours (p = 0.017), high Ki-67 (p = 0.008), high histologic grade (p<0.001), HER2+ expression (p<0.001), and non-lobular histologic type (p = 0.012) were predictive factors for pCR. The multivariate model revealed that HER2 expression (p<0.001) and Ki-67 (p = 0.005) were independent predictors. Conclusion: Neoadjuvant chemotherapy demonstrated e ectiveness in ND-BC patients, leading to favourable pCR rates and enabling breast-conserving surgery. Predictive markers for pCR varied depending on histologic types, with HER2 expression, ER status, Ki-67, and histologic grade showing signi cance in non-ductal subtypes, while HER2 status alone was predictive in lobular carcinoma.
Publication Details
Page(s) 37-41
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
Neoadjuvant chemotherapy, Non-ductal breast cancer, Lobular carcinoma
0

Citations

0

Downloads

77

Views